Procurement Summary
Country: Slovakia
Summary: Medicine with the Active Substance Cerliponase Alfa 150 Mg, Infusion Solution
Deadline: 10 Sep 2026
Posting Date: 05 Aug 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 146594296
Document Ref. No.: 543540-2026
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: EUR 2678664.6
CPV Classification
33610000 - Medicinal products for the alimentary tract and metabolism
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details
Tender Details
Medicine with the active substance cerliponase alfa 150 mg, infusion solution The subject of the order is Medicine with the active substance cerliponase alfa 150 mg, infusion solution Pharmaceutical form: sol inf 5 ml/150 mg+5 ml diluted solution (drug.inj.glass) Administration: intracerebroventricular use The drug cerliponase alfa belongs to a group of drugs known as enzyme replacement therapies. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. People with with CLN2 disease, they lack or have too little of an enzyme called TPP1, which causes a build-up of substances called lysosomal storage substances. In people with CLN2 disease, these substances accumulate in some parts of the body, especially in the brain. This medicine replaces the missing one an enzyme called TPPA, thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing down the progression of the disease. The recommended dose is 300 mg of cerliponase alfa administered once every two weeks by intracerebroventricular infusion. Doc Title: Medicine with the active substance cerliponase alfa 150 mg, infusion solution Contract Type: supplies
Document Type: Contract Notice Reference Number: 63-2026 Contract Type: supplies Estimated Value: 2678664.6 - EUR Authority Type: body-pl-cga Doc Title: Medicine with the active substance cerliponase alfa 150 mg, infusion solution Dispatch Date: 2026-08-04 Publish Date: 2026-08-05 Submission Date: 2026-09-10
Documents
Tender Notice